Last reviewed · How we verify

Trinity Health Of New England — Portfolio Competitive Intelligence Brief

Trinity Health Of New England pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Arformoterol (Brovana) Arformoterol (Brovana) marketed Long-acting beta-2 agonist (LABA) Beta-2 adrenergic receptor Respiratory

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. AstraZeneca · 1 shared drug class
  2. Chiesi Farmaceutici S.p.A. · 1 shared drug class
  3. Dey · 1 shared drug class
  4. Fundacio Privada Mon Clinic Barcelona · 1 shared drug class
  5. Genentech, Inc. · 1 shared drug class
  6. GlaxoSmithKline · 1 shared drug class
  7. Henan University of Traditional Chinese Medicine · 1 shared drug class
  8. Novartis · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Trinity Health Of New England:

Cite this brief

Drug Landscape (2026). Trinity Health Of New England — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/trinity-health-of-new-england. Accessed 2026-05-17.

Related